{"id":"W2047170994","doi":"10.1016/j.neurobiolaging.2012.03.006","title":"Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative","year":2012,"lang":"en","type":"article","venue":"Neurobiology of Aging","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"National Institute of General Medical Sciences; National Institute on Aging; University of California, Los Angeles; Canadian Institutes of Health Research; Genentech; National Institutes of Health; Servier; Eisai; Northern California Institute for Research and Education; University of California, San Diego; Pfizer; Biogen; BioClinica; Alzheimer's Association; Amorfix Life Sciences; F. Hoffmann-La Roche; Medpace; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; Bayer HealthCare; Meso Scale Diagnostics; Alzheimer's Disease Neuroimaging Initiative; Novartis Pharmaceuticals Corporation; Synarc","keywords":"Clinical Dementia Rating; Dementia; Neuroimaging; Alzheimer's disease; Alzheimer's Disease Neuroimaging Initiative; Population; Psychology; Biomarker; Rating scale; Disease; Clinical trial; Sample size determination; Cognition; Cognitive decline; Audiology; Clinical psychology; Psychiatry; Medicine; Internal medicine; Developmental psychology; Biology; Genetics","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021582,0.0002272638,0.0004908085,0.000169026,0.0002531398,0.00002374642,0.0001662489,0.00004139034,0.0003927203],"category_scores_gemma":[0.002984792,0.0001536333,0.0002673607,0.0001565865,0.0002479464,0.0001240647,0.00008663665,0.0002352224,0.000009827888],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001147313,"about_ca_system_score_gemma":0.0001231292,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000009320103,"about_ca_topic_score_gemma":2.649439e-7,"domain_scores_codex":[0.9975432,0.0007799755,0.0005146479,0.000332262,0.000225905,0.0006039642],"domain_scores_gemma":[0.9926237,0.006391154,0.0003087776,0.0003123562,0.0001737588,0.0001902569],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00329317,0.002007945,0.9377476,0.0003497627,0.002681532,0.00002022732,0.0008453748,0.0007131564,0.01252682,0.001472419,0.005793693,0.03254833],"study_design_scores_gemma":[0.007663371,0.00246286,0.8299229,0.0005998596,0.006494745,0.00001203696,0.0004025205,0.03818108,0.1109429,0.001036554,0.001707192,0.0005739716],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9416276,0.002208411,0.02012966,0.0225003,0.001595521,0.007206195,0.0004616034,0.000235924,0.004034744],"genre_scores_gemma":[0.9911422,0.000006753795,0.004020916,0.004126538,0.0003109727,0.0002401188,0.0001122289,0.00003420548,0.000006028155],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1078247,"threshold_uncertainty_score":0.6264986,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1361356262326201,"score_gpt":0.3888516976460014,"score_spread":0.2527160714133814,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}